



ESMO ADVANCED COURSE

LISBON PORTUGAL **5-6 MAY 2023**

Co-Chairs

Pilar Garrido López, Spain Nikolas von Bubnoff, Germany

PRECISION ONCOLOGY ACROSS TUMOURS: TUMOUR-AGNOSTIC AND TUMOUR-MODULATED (MSI and TMB, NTRK, BRAF, HRD)

Lisbon, Portugal 5-6 May 2023

CO-CHAIRS

Pilar Garrido López, Spain Nikolas von Bubnoff, Germany **SPEAKERS**

Benjamin Besse, France Tilman Brummer, Germany Hauke Busch, Germany Ilaria Colombo, Switzerland Lizza Hendriks, Netherlands Fernando López-Ríos, Spain

LEARNING OBJECTIVES

- To understand the biology of MSI/HRD, TMB, NTRK and BRAF and the frequency of these biomarkers across entities
- To learn the diagnostic tools, the clinical significance of specific variants and specify the actionability and level of evidence with regard to personalized treatment recommendations

ACCREDITATION

The programme of this event has been accredited with **7 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from





ORGANISATION AND CONTACTS

ESMO Head Office Education Department Via Ginevra 4, 6900 Lugano Switzerland

Email: courses@esmo.org

www.esmo.org



Friday, 5 May 2023

09:00-09:10	Welcome and introduction
10'	Welcome and Learning Objectives Introduction Pilar Garrido López, ES and Nikolas von Bubnoff, DE
09:10-10:30	Session 1 – Molecular target / Family of targets – MSI and TMB Chair: Nikolas von Bubnoff, DE
15'	Biology of the target / biomarkers (function and roles in normal and tumour tissue homeostasis) Hauke Busch, DE
5'	Q&A
15'	Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity Lizza Hendriks, NL
5'	Q&A
15'	Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation) Hauke Busch, DE
5'	Q&A
15'	A clinicopathological case presented and discussed by a Molecular Tumour Board Lizza Hendriks, NL
5'	Q&A
10:30-11:00	Coffee break
<i>10:30-11:00</i> 11:00-12:35	Coffee break Session 2 – Molecular target / Family of targets – NTRK Chairs: Pilar Garrido López, ES and Fernando López-Ríos, ES
	Session 2 – Molecular target / Family of targets – NTRK Chairs: Pilar Garrido López, ES and Fernando López-Ríos, ES Biology of the target / biomarkers (function and roles in normal and tumour tissue homeostasis)
11:00-12:35	Session 2 – Molecular target / Family of targets – NTRK Chairs: Pilar Garrido López, ES and Fernando López-Ríos, ES
11:00-12:35 15'	Session 2 – Molecular target / Family of targets – NTRK Chairs: Pilar Garrido López, ES and Fernando López-Ríos, ES Biology of the target / biomarkers (function and roles in normal and tumour tissue homeostasis) Fernando López-Ríos, ES Q&A Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity
11:00-12:35 15' 5'	Session 2 – Molecular target / Family of targets – NTRK Chairs: Pilar Garrido López, ES and Fernando López-Ríos, ES Biology of the target / biomarkers (function and roles in normal and tumour tissue homeostasis) Fernando López-Ríos, ES Q&A
11:00-12:35 15' 5' 15'	Session 2 – Molecular target / Family of targets – NTRK Chairs: Pilar Garrido López, ES and Fernando López-Ríos, ES Biology of the target / biomarkers (function and roles in normal and tumour tissue homeostasis) Fernando López-Ríos, ES Q&A Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity Pilar Garrido López, ES Q&A Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)
11:00-12:35 15' 5' 15' 5'	Session 2 – Molecular target / Family of targets – NTRK Chairs: Pilar Garrido López, ES and Fernando López-Ríos, ES Biology of the target / biomarkers (function and roles in normal and tumour tissue homeostasis) Fernando López-Ríos, ES Q&A Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity Pilar Garrido López, ES Q&A
11:00-12:35 15' 5' 15' 5' 20'	Session 2 – Molecular target / Family of targets – NTRK Chairs: Pilar Garrido López, ES and Fernando López-Ríos, ES Biology of the target / biomarkers (function and roles in normal and tumour tissue homeostasis) Fernando López-Ríos, ES Q&A Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity Pilar Garrido López, ES Q&A Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation) Fernando López-Ríos, ES Q&A A clinicopathological case presented and discussed by a Molecular Tumour Board
11:00-12:35 15' 5' 15' 5' 20' 10'	Session 2 – Molecular target / Family of targets – NTRK Chairs: Pilar Garrido López, ES and Fernando López-Ríos, ES Biology of the target / biomarkers (function and roles in normal and tumour tissue homeostasis) Fernando López-Ríos, ES Q&A Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity Pilar Garrido López, ES Q&A Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation) Fernando López-Ríos, ES Q&A

13:35-15:10	Session 3 – Molecular target / Family of targets – BRAF Chairs: Tilman Brummer, DE and Nikolas von Bubnoff, DE
15'	Biology of the target / biomarkers (function and roles in normal and tumour tissue homeostasis) Tilman Brummer, DE
5'	Q&A
15'	Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity Benjamin Besse, FR
5'	Q&A
20'	Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation) Tilman Brummer, DE
10'	Q&A
15'	A clinicopathological case presented and discussed by a Molecular Tumour Board Nikolas von Bubnoff, DE
10'	Q&A
15:10-15:40	Coffee break
19:30	Networking Dinner

Saturday, 6 May 2023

09:00-11:50	Session 4 – <i>Molecular target / Family of targets – HRD</i> Chairs: Pilar Garrido López, ES and Nikolas von Bubnoff, DE
15'	Biology of the target / biomarkers (function and roles in normal and tumour tissue homeostasis) Hauke Busch, DE
15'	Q&A
15'	Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity Ilaria Colombo, CH
15'	Q&A
10:00-10:30	Coffee break
20'	Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation) Hauke Busch, DE
20'	Q&A
30'	Value / health economics of testing Fernando López-Ríos, ES
10'	Q&A
11:50-12:00	Synthesis and wrap-up
12:00-13:00	Lunch